MyMD Pharmaceuticals, Inc. ( MYMD) Stock. Should you Buy or Sell? $ 3.59
-0.09 (-2.57 %)
MyMD Pharmaceuticals, Inc. Analysis
Updated on 10-09-2022| Symbol | MYMD |
| Price | $3.59 |
| Beta | 0.287 |
| Volume Avg. | $287.39 thousand |
| Market Cap | $136.63 M |
| 52 Week Range | $1.88 - $9.95 |
MyMD Pharmaceuticals, Inc. opened the day at $3.59 which is -2.57 % on yesterday's close. MyMD Pharmaceuticals, Inc. has a 52 week high of $9.95 and 52 week low of $1.88, which is a difference of $8.07. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $136.63 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy MyMD Pharmaceuticals, Inc. for $136.63 M, it would take 15 years to get your money back. MyMD Pharmaceuticals, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
MyMD Pharmaceuticals, Inc. Stock Forecast - Is MyMD Pharmaceuticals, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Strong Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -0.005 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.000 |
Valuing MyMD Pharmaceuticals, Inc.
| Price Book Value Ratio | 8.536 | Price To Book Ratio | 8.536 |
| Price To Sales Ratio | 0.000 | Price Earnings Ratio | -0.005 |
How liquid is MyMD Pharmaceuticals, Inc.
| Current Ratio | 2.409 |
| Quick Ratio | 1.936 |
Debt
| Debt Ratio | 0.159 | Debt Equity Ratio | 0.189 |
| Long Term Debt To Capitalization | 0.007 | Total Debt To Capitalization | 0.011 |
Latest news about MyMD Pharmaceuticals, Inc.
Here's what you need to know about trading penny stocks on July 11th The post What to Know About Buying Penny Stocks on July 11th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Benchmark Company Discovery Conference Date: December 2, 2021 Format: 1-on-1 meetings (virtual) Registration: Click here Benzinga Global Small Cap Conference Dates: December 8-9, 2021 Format: Present
Two new Breakout Stocks for Week 44 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges, the portfolio is up +68.8% YTD despite a record high 24 weeks out 43 weeks this year in negative conditions above the 40 MG level.
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. The conference is being held at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D.
BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced new data demonstrating Supera-CBD's superior potency over CBD by factor of 8,000 times. Supera-CBD is MyMD's pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. The study was conducted by Eurofins D
About MyMD Pharmaceuticals, Inc.
Description :
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
